Agalsidase beta is an intravenous enzyme replacement therapy for patients with Fabry disease.1 The mechanism of action of agalsidase beta is presented in Figure 1. The availability of agalsidase beta differs between countries. For further information, please consult your local prescribing information.

Figure 1.
Mechanism of action of agalsidase beta.1,2

C-ANPROM/INT/FAB/0017; Date of preparation: March 2021